Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
Phase: EARLY_PHASE1
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation, Loss of Chromosome 17p, Mantle Cell Lymphoma, Minimal Residual Disease, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, RAS Family Gene Mutation, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hematologic Malignancy, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, TP53 Gene Mutation
Sponsor: Rutgers, The State University of New Jersey

 
 
Official Title: 
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells 
NCT number: 
NCT03272633 
Document Type:  
Protocol and SAP 
Date of the 
Document: 
04/23/2021 
 
 

Title of Project: Post-Transplant Use of Irradiated Allogeneic Cells 
Principal Investigator: 
Sub-investigators: 
Funding Source(s): Funded from philanthropic funds to Rutgers Cancer Institute of New 
Jersey 
IND Number: 011,270 
CONFIDENTIAL 
NCI 
RESERVED FOR !RB STAMP 
DO NOT MODIFY THIS SPACE 
Form Version 
Approval Date: 
Expiration Date: 
4/23 2021 
4/22 2022 

Protocol Number: 011702
PI Name: Roger Strair, MD, PhD
Protocol Title: Post-Transplant Use of Irradiated 
Allogeneic Cells
Version date:  4/22/2019
25
RESERVED FOR IRB STAMP
DO NOT MODIFY THIS SPACE
Form Version v120116
9) Bibliography
1.
Katz DH, Benacerraf B. The regulatory influence of activated T cells on B cell responses to 
antigen. Advances in immunology. 1972;15:1-94.
2.
Katz DH, Ellman L, Paul WE, Green I, Benacerraf B. Resistance of guinea pigs to leukemia 
following transfer of immunocompetent allogeneic lymphoid cells. Cancer research. 
1972;32(1):133-40.
3.
Katz DH, Paul WE, Goidl EA, Benacerraf B. Carrier function in anti-hapten antibody 
responses. 3. Stimulation of antibody synthesis and facilitation of hapten-specific secondary 
antibody responses by graft-versus-host reactions. The Journal of experimental medicine. 
1971;133(2):169-86.
4.
Ellman L, Katz DH, Green I, Paul WE, Benacerraf B. Mechanisms involved in the 
antileukemic effect of immunocompetent allogeneic lymphoid cell transfer. Cancer research. 
1972;32(1):141-8.
5.
Symons HJ, Levy MY, Wang J, Zhou X, Zhou G, Cohen SE, et al. The allogeneic effect 
revisited: exogenous help for endogenous, tumor-specific T cells. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow Transplantation. 
2008;14(5):499-509.
6.
Strair RK, Schaar D, Medina D, Todd MB, Aisner J, DiPaola RS, et al. Antineoplastic effects 
of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 
2003;21(20):3785-91.
7.
Medina DJ, Gharibo M, Savage P, Cohler A, Kuriyan M, Balsara B, et al. A pilot study of 
allogeneic cellular therapy for patients with advanced hematologic malignancies. Leukemia 
research. 2008;32(12):1842-8.
           4/23/2021
           4/22/2022